CN106029901A - 用于抗精神病药诱导的增重的遗传标志物及其使用方法 - Google Patents
用于抗精神病药诱导的增重的遗传标志物及其使用方法 Download PDFInfo
- Publication number
- CN106029901A CN106029901A CN201480069450.4A CN201480069450A CN106029901A CN 106029901 A CN106029901 A CN 106029901A CN 201480069450 A CN201480069450 A CN 201480069450A CN 106029901 A CN106029901 A CN 106029901A
- Authority
- CN
- China
- Prior art keywords
- seq
- polymorphisms
- subject
- antipsychotic
- gabra2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000000561 anti-psychotic effect Effects 0.000 title claims description 41
- 235000019786 weight gain Nutrition 0.000 title description 37
- 230000004584 weight gain Effects 0.000 title description 36
- 230000002068 genetic effect Effects 0.000 title description 12
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 50
- 238000011282 treatment Methods 0.000 claims abstract description 41
- 101150099997 GABRA2 gene Proteins 0.000 claims abstract description 31
- 230000004044 response Effects 0.000 claims abstract description 26
- 230000008859 change Effects 0.000 claims abstract description 17
- 229940124604 anti-psychotic medication Drugs 0.000 claims abstract description 7
- 239000012472 biological sample Substances 0.000 claims abstract description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 45
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 34
- 208000028017 Psychotic disease Diseases 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 31
- 208000024891 symptom Diseases 0.000 claims description 29
- 208000022610 schizoaffective disease Diseases 0.000 claims description 20
- 102000017695 GABRA2 Human genes 0.000 claims description 16
- 101000893333 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-2 Proteins 0.000 claims description 16
- 238000009396 hybridization Methods 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 11
- 238000012544 monitoring process Methods 0.000 claims description 11
- 208000031648 Body Weight Changes Diseases 0.000 claims description 10
- 230000004579 body weight change Effects 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000001712 DNA sequencing Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108060002716 Exonuclease Proteins 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 102000013165 exonuclease Human genes 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims 1
- 238000003149 assay kit Methods 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 238000000151 deposition Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 32
- 229960004170 clozapine Drugs 0.000 description 22
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 22
- 102000054766 genetic haplotypes Human genes 0.000 description 22
- 229960005017 olanzapine Drugs 0.000 description 18
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 16
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 229940127236 atypical antipsychotics Drugs 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 12
- 238000010197 meta-analysis Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000012552 review Methods 0.000 description 11
- 239000000164 antipsychotic agent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- 229940005529 antipsychotics Drugs 0.000 description 8
- 239000003693 atypical antipsychotic agent Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 7
- 230000002974 pharmacogenomic effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229960001534 risperidone Drugs 0.000 description 7
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 238000003205 genotyping method Methods 0.000 description 6
- 229960003878 haloperidol Drugs 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- -1 allopregnenolone Chemical class 0.000 description 5
- 229960005245 asenapine Drugs 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229960001432 lurasidone Drugs 0.000 description 5
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000009897 systematic effect Effects 0.000 description 5
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 4
- 102000054930 Agouti-Related Human genes 0.000 description 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 4
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229960004372 aripiprazole Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229960003162 iloperidone Drugs 0.000 description 4
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 229960001057 paliperidone Drugs 0.000 description 4
- 229960000607 ziprasidone Drugs 0.000 description 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108090000839 GABA-A Receptors Proteins 0.000 description 3
- 102000004300 GABA-A Receptors Human genes 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 108010008364 Melanocortins Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010057852 Nicotine dependence Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- 208000025569 Tobacco Use disease Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 229960000423 loxapine Drugs 0.000 description 3
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 3
- 239000002865 melanocortin Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229960004431 quetiapine Drugs 0.000 description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 102000027484 GABAA receptors Human genes 0.000 description 2
- 108091008681 GABAA receptors Proteins 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 208000030990 Impulse-control disease Diseases 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 230000004590 drinking behavior Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000004050 mood stabilizer Substances 0.000 description 2
- 229940127237 mood stabilizer Drugs 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- SFXPZLCQRZASKK-UHFFFAOYSA-N (3alpha,5alpha)-3-Hydroxypregn-16-en-20-one Natural products C1CC2CC(O)CCC2(C)C2C1C1CC=C(C(=O)C)C1(C)CC2 SFXPZLCQRZASKK-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- SFXPZLCQRZASKK-CKBUFISISA-N 1-[(3s,5s,8r,9s,10s,13s,14s)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC=C(C(=O)C)[C@@]2(C)CC1 SFXPZLCQRZASKK-CKBUFISISA-N 0.000 description 1
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 description 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000611734 Ficedula albicollis Species 0.000 description 1
- 241000204742 Ficedula hypoleuca Species 0.000 description 1
- 230000009165 GABAergic signaling Effects 0.000 description 1
- 241000287826 Gallus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000942140 Muscicapa striata Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 241000190070 Sarracenia purpurea Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000013180 random effects model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892094P | 2013-10-17 | 2013-10-17 | |
| US61/892,094 | 2013-10-17 | ||
| PCT/CA2014/051000 WO2015054792A1 (en) | 2013-10-17 | 2014-10-17 | Genetic markers for antipsychotic induced weight gain and methods for use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106029901A true CN106029901A (zh) | 2016-10-12 |
Family
ID=52827506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480069450.4A Pending CN106029901A (zh) | 2013-10-17 | 2014-10-17 | 用于抗精神病药诱导的增重的遗传标志物及其使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10301678B2 (enExample) |
| EP (2) | EP3058106B1 (enExample) |
| JP (1) | JP6524073B2 (enExample) |
| KR (1) | KR102252926B1 (enExample) |
| CN (1) | CN106029901A (enExample) |
| AU (1) | AU2014336928B2 (enExample) |
| CA (1) | CA2943951C (enExample) |
| ES (1) | ES2728072T3 (enExample) |
| IL (1) | IL245159B (enExample) |
| PT (1) | PT3058106T (enExample) |
| SG (1) | SG11201602998QA (enExample) |
| WO (1) | WO2015054792A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317868A (zh) * | 2019-08-09 | 2019-10-11 | 新疆医科大学第二附属医院 | 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法 |
| CN112105931A (zh) * | 2018-02-09 | 2020-12-18 | 代谢组学诊断有限公司 | 用代谢生物标记物和蛋白质生物标记物预测子痫前期早产的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070292962A1 (en) * | 2006-04-10 | 2007-12-20 | Duke University | Methods and compositions for genetic markers for autism |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| CA2176348C (en) | 1993-11-12 | 2004-11-02 | Sanjay Tyagi | Hybridization probes for nucleic acid detection, universal stems, methods and kits |
| US20030108938A1 (en) * | 2001-11-06 | 2003-06-12 | David Pickar | Pharmacogenomics-based clinical trial design recommendation and management system and method |
| US8012718B2 (en) | 2006-03-31 | 2011-09-06 | Genomas, Inc. | Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs |
| US7795033B2 (en) | 2007-03-19 | 2010-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods to predict the outcome of treatment with antidepressant medication |
| US8476012B2 (en) | 2008-04-18 | 2013-07-02 | Genomas, Inc. | Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| CN104114714A (zh) | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
-
2014
- 2014-10-17 US US15/029,955 patent/US10301678B2/en active Active
- 2014-10-17 CA CA2943951A patent/CA2943951C/en active Active
- 2014-10-17 KR KR1020167012720A patent/KR102252926B1/ko not_active Expired - Fee Related
- 2014-10-17 JP JP2016524143A patent/JP6524073B2/ja not_active Expired - Fee Related
- 2014-10-17 EP EP14854407.5A patent/EP3058106B1/en not_active Not-in-force
- 2014-10-17 ES ES14854407T patent/ES2728072T3/es active Active
- 2014-10-17 WO PCT/CA2014/051000 patent/WO2015054792A1/en not_active Ceased
- 2014-10-17 AU AU2014336928A patent/AU2014336928B2/en not_active Ceased
- 2014-10-17 PT PT14854407T patent/PT3058106T/pt unknown
- 2014-10-17 SG SG11201602998QA patent/SG11201602998QA/en unknown
- 2014-10-17 CN CN201480069450.4A patent/CN106029901A/zh active Pending
- 2014-10-17 EP EP19159011.6A patent/EP3561076A1/en not_active Withdrawn
-
2016
- 2016-04-17 IL IL245159A patent/IL245159B/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070292962A1 (en) * | 2006-04-10 | 2007-12-20 | Duke University | Methods and compositions for genetic markers for autism |
Non-Patent Citations (3)
| Title |
|---|
| BAUER L.O.等: "GABRA2 genotype, impulsivity and body mass", 《AM.J.ADDICT.》 * |
| VANESSA F.G.等: "A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia", 《NEUROPSYCHOPHARMACOLOGY》 * |
| 张志等: "抗精神病药物所致体重增加的药物遗传学研究", 《国外医学.精神病学分册》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105931A (zh) * | 2018-02-09 | 2020-12-18 | 代谢组学诊断有限公司 | 用代谢生物标记物和蛋白质生物标记物预测子痫前期早产的方法 |
| CN110317868A (zh) * | 2019-08-09 | 2019-10-11 | 新疆医科大学第二附属医院 | 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法 |
| CN110317868B (zh) * | 2019-08-09 | 2020-05-19 | 新疆医科大学第二附属医院 | 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016534715A (ja) | 2016-11-10 |
| PT3058106T (pt) | 2019-05-30 |
| SG11201602998QA (en) | 2016-05-30 |
| ES2728072T3 (es) | 2019-10-22 |
| KR102252926B1 (ko) | 2021-05-20 |
| AU2014336928B2 (en) | 2020-07-16 |
| CA2943951A1 (en) | 2015-04-23 |
| IL245159B (en) | 2020-10-29 |
| WO2015054792A1 (en) | 2015-04-23 |
| CA2943951C (en) | 2022-05-31 |
| KR20160098188A (ko) | 2016-08-18 |
| EP3058106B1 (en) | 2019-02-27 |
| US10301678B2 (en) | 2019-05-28 |
| IL245159A0 (en) | 2016-06-30 |
| EP3561076A1 (en) | 2019-10-30 |
| EP3058106A1 (en) | 2016-08-24 |
| EP3058106A4 (en) | 2017-06-07 |
| JP6524073B2 (ja) | 2019-06-05 |
| US20160237499A1 (en) | 2016-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder | |
| Anitha et al. | Genetic analyses of roundabout (ROBO) axon guidance receptors in autism | |
| Wang et al. | The—1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients | |
| AU2015222658A1 (en) | Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain | |
| Seneviratne et al. | Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence | |
| WO2008086579A1 (en) | Diagnostic methods and agents | |
| Kishi et al. | Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients | |
| KR20160111925A (ko) | 자살 위험과 연관된 유전적 마커 및 그의 사용 방법 | |
| JP2020089370A (ja) | 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法 | |
| JP6524073B2 (ja) | 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法 | |
| EP2087136A2 (en) | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication | |
| AU2014336928A1 (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| CA2664366C (en) | Slc1a1 antipsychotic drug response markers | |
| US20140045717A1 (en) | Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism | |
| CN104946738B (zh) | 内脏脂肪蓄积易感性的判定方法 | |
| EP1756314A1 (en) | Biomarkers for the prediction of responsiveness to clozapine treatment | |
| HK1224705B (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| HK1224705A1 (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| KR20070022710A (ko) | 클로자핀 치료에 대한 반응성을 예측하기 위한 바이오마커 | |
| EP2314714A1 (en) | Disease susceptibility | |
| Kim et al. | P. 1. a. 013 Antipsychotics-induced weight gain is associated with therapeutic response and the polymorphism of dopamine D3 receptor gene in Korean schizophrenia | |
| CA2517218A1 (en) | Marker for psychosis or mood disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161012 |